Premarket Approval (PMA) is the FDA’s most stringent premarket review pathway for Class III medical devices. Governed by 21 CFR Part 814 and Section 515 of the FD&C Act, it requires an applicant to demonstrate reasonable assurance of safety and effectiveness through valid scientific evidence, usually including clinical data, before US marketing.
What is Premarket Approval (PMA)?
Premarket Approval (PMA) is the review process the FDA uses to decide whether a Class III medical device is safe and effective enough to enter the US market. Class III covers the highest-risk devices: those that support or sustain life, are implanted, or present a potential unreasonable risk of illness or injury, such as heart valves, implantable defibrillators, and certain high-risk diagnostic systems.
Unlike a 510(k), which relies on substantial equivalence to a legally marketed predicate, a PMA stands on its own scientific record. The applicant builds the case for approval from clinical and nonclinical evidence rather than comparison. A Class III device that fails to meet PMA requirements is considered adulterated under Section 501(f) of the FD&C Act and cannot be legally marketed.
Why Premarket Approval (PMA) matters in medical device development
The stakes sit at the top end of device regulation. Class III devices carry the highest patient risk, so the evidence bar is correspondingly high, and the consequences of getting it wrong reach past a rejected file.
A PMA program is expensive and long. Clinical studies alone can run for years, and the FDA works to an 180-day statutory review clock from the point a PMA is accepted for filing, though real timelines usually extend well beyond that once deficiency letters and amendments are counted. Every month of delay pushes back revenue and burns runway.
Approval is also conditional. The FDA can attach post-approval requirements, mandate post-approval studies, and inspect the manufacturing site before it grants approval. Since February 2, 2026, those preapproval inspections are assessed under the Quality Management System Regulation (QMSR), which incorporates ISO 13485:2016 into 21 CFR Part 820. A weak quality system can stall an otherwise strong submission.
How the Premarket Approval (PMA) process works
A PMA is a structured submission under 21 CFR Part 814.20. The core building blocks are consistent across programs:
- Device description: technical specifications, principles of operation, materials, and components.
- Nonclinical data: bench testing, biocompatibility per ISO 10993, sterilization, shelf life, and software validation where applicable. Safety studies follow Good Laboratory Practice under 21 CFR Part 58.
- Clinical data: results from well-controlled investigations, usually run under an Investigational Device Exemption (IDE), that show reasonable assurance of safety and effectiveness.
- Manufacturing information: the quality system and processes used to make the device, now mapped to ISO 13485:2016 under the QMSR.
- Labeling: indications for use, instructions, and risk information.
After submission, the FDA runs an acceptance and filing review, then a substantive scientific review. Novel or high-risk devices are often referred to an advisory panel of outside experts. The agency may also conduct a pre-approval facility inspection before deciding. Once a device is approved, changes are handled through PMA supplements under 21 CFR Part 814.39, each reviewed against the same standard as the original.
Common challenges and best practices
The most common failure is thin clinical evidence. Teams underpower studies, pick endpoints the FDA will not accept, or skip the pre-submission (Q-Sub) meetings where those issues surface early. Engaging the FDA before locking a study protocol saves cycles later.
Documentation gaps are the second trap. A PMA pulls together design, risk management under ISO 14971, verification and validation, and manufacturing records into one coherent story. When those records were not built for outside scrutiny, assembling the submission becomes a scramble.
Quality system readiness now carries extra weight. With preapproval inspections assessed against the QMSR since early 2026, a facility that cannot show risk-based, ISO 13485-aligned processes risks a finding that delays approval. Strong programs treat the quality system, the clinical strategy, and the submission as one workstream from the start.
How SJML helps with Premarket Approval (PMA)
A Class III program stretches across regulatory strategy, clinical evidence, quality systems, and manufacturing, and SJML works across all of them as an end-to-end CDMO. Its QARA team supports device classification and regulatory strategy, builds and remediates ISO 13485 quality systems, and prepares the technical documentation and design history files a submission draws on. Risk management under ISO 14971, clinical evaluation, and clinical data management round out the support, so the evidence and the quality record are ready for FDA review rather than being reconstructed under a deadline.
Frequently asked questions
A 510(k) clears a device by showing it is substantially equivalent to a legally marketed predicate, and it applies mostly to Class II devices. A Premarket Approval (PMA) applies to Class III devices and requires independent scientific proof of safety and effectiveness, usually including clinical data. A PMA is more rigorous, more expensive, and takes considerably longer than a 510(k).
The FDA works to an 180-day statutory review period once a PMA is accepted for filing, but the full journey is usually far longer. Clinical studies can add years before submission, and review often extends past 180 days when the agency issues deficiency letters and the applicant responds with amendments. Most Class III programs should plan for a multi-year timeline end-to-end.
Class III devices require a Premarket Approval unless they qualify for another route. These are the highest-risk devices, including many implants, life-supporting or life-sustaining products, and certain novel diagnostics. Examples include implantable pacemakers, heart valves, and some high-risk in vitro diagnostic systems. If a Class III device has no established PMA requirement in its regulation, a Class III 510(k) may apply instead.
Often, yes. The FDA can conduct a preapproval inspection of the manufacturing facility before it grants a PMA, and it can also inspect after approval. Since February 2, 2026, these inspections are assessed under the Quality Management System Regulation, which incorporates ISO 13485:2016. A facility that cannot show a compliant, risk-based quality system can see approval delayed even when the technical file is strong.
Related terms
- 510(k) Premarket Notification
- Investigational Device Exemption (IDE)
- Class III Medical Device
- Quality Management System Regulation (QMSR)
- De Novo Classification
